↑ トップへ　← 戻る

 Drug（薬物リスト） DrugBank | All Description Patterns

   e.g. "Sirolimus", "アダリムマブ"

A　B　C　D　E　F　G　H　 I 　J　K　L　M　N　O　P　Q　R　S　T　U　V　W　X　Y　Z　other

55 / 12,170 descriptions found* Show info (disease name, etc.) on mouse-over.
 No.   薬物名（臨床試験情報から抽出）   DrugBank   KEGG DRUG *   KEGG GENES *   KEGG PATHWAY   指定難病告示番号 * 
 1   Acetate   Acetate   -   -   -   40件:
1,
2,
6,
10,
13,
35,
40,
46,
49,
51,
60,
64,
70,
71,
73,
75,
76,
78,
81,
83,
85,
86,
88,
90,
96,
97,
113,
145,
156,
162,
171,
206,
222,
224,
225,
235,
265,
288,
298,
299 
 2   Alx-0081   -   -   -   -   1件:
64 
 3   Anfibatide   Anfibatide   -   -   -   1件:
64 
 4   Anti-von willebrand factor nanobody   Von willebrand factor human   -   -   -   1件:
64 
 5   Anti-von willebrand factor nanobody, inn = caplacizumab   Caplacizumab   D11160   1件: VWF   6件: Complement and coagulation cascades, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, PI3K-Akt signaling pathway, Platelet activation   1件:
64 
 6   Apadamtase alfa   Apadamtase alfa   -   -   -   1件:
64 
 7   Arc 1779   -   -   -   -   2件:
64,
288 
 8   Arc1779   -   -   -   -   2件:
64,
288 
 9   Arc1779 injection   -   -   -   -   2件:
64,
288 
 10   Bax930   -   -   -   -   1件:
64 
 11   Bax930 or shp655   -   -   -   -   1件:
64 
 12   Caplacizumab   Caplacizumab   D11160   1件: VWF   6件: Complement and coagulation cascades, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, PI3K-Akt signaling pathway, Platelet activation   1件:
64 
 13   Caplacizumab (alx-0081)   Caplacizumab   D11160   1件: VWF   6件: Complement and coagulation cascades, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, PI3K-Akt signaling pathway, Platelet activation   1件:
64 
 14   Caplacizumab (an anti-von willebrand factor nanobody alx-0081)   Caplacizumab   D11160   1件: VWF   6件: Complement and coagulation cascades, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, PI3K-Akt signaling pathway, Platelet activation   1件:
64 
 15   Caplacizumab (an anti-von willebrand factor nanobody)   Caplacizumab   D11160   1件: VWF   6件: Complement and coagulation cascades, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, PI3K-Akt signaling pathway, Platelet activation   1件:
64 
 16   Corticosteroid treatment (methylprednisolone or prednisolone)   Methylprednisolone   D00407, D00751, D00979, D05000, D05001, D05002   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
64 
 17   Corticosteroids   -   -   -   -   9件:
41,
46,
49,
64,
97,
164,
220,
296,
300 
 18   Cryosupernatant plasma   -   -   -   -   1件:
64 
 19   Cyclosporine   Ciclosporin   D00184   5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   33件:
11,
14,
19,
20,
28,
36,
40,
41,
42,
45,
46,
49,
50,
53,
56,
58,
60,
62,
64,
65,
90,
95,
97,
162,
164,
222,
226,
228,
234,
283,
284,
285,
302 
 20   Danazol   Danazol   D00289   3件: AR, ESR1, PGR   11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway   4件:
60,
64,
65,
285 
 21   Desmopressin   Desmopressin   D00291, D02235   2件: AVPR2, F8   4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption   5件:
6,
64,
72,
225,
288 
 22   Desmopressin acetate   Desmopressin   D00291, D02235   2件: AVPR2, F8   4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption   2件:
64,
288 
 23   Hmed-ides   Imlifidase   D11470   -   -   2件:
64,
221 
 24   Idec-c2b8   Rituximab   D02994   1件: MS4A1   1件: Hematopoietic cell lineage   1件:
64 
 25   Idec-c2b8, ro 45-2294   Rituximab   D02994   1件: MS4A1   1件: Hematopoietic cell lineage   1件:
64 
 26   Ides   -   -   -   -   1件:
64 
 27   Ides (0.25 mg/kg)   -   -   -   -   1件:
64 
 28   Ides (0.50 mg/kg)   -   -   -   -   1件:
64 
 29   Immunosuppressive treatment (eg, rituximab)   Rituximab   D02994   1件: MS4A1   1件: Hematopoietic cell lineage   1件:
64 
 30   Mabthera   -   -   -   -   15件:
11,
13,
35,
46,
50,
51,
53,
61,
63,
64,
65,
83,
162,
222,
271 
 31   Magnesium   Magnesium   -   -   -   15件:
6,
11,
13,
46,
64,
93,
97,
166,
225,
235,
284,
291,
296,
297,
298 
 32   Methylprednisolone   Methylprednisolone   D00407, D00751, D00979, D05000, D05001, D05002   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   36件:
2,
13,
25,
26,
35,
38,
39,
40,
41,
42,
43,
45,
46,
49,
50,
51,
60,
63,
64,
65,
66,
83,
84,
86,
96,
97,
145,
164,
220,
222,
224,
271,
283,
284,
285,
296 
 33   Minirin   Desmopressin   D00291, D02235   2件: AVPR2, F8   4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption   2件:
64,
288 
 34   Octaplas   -   -   -   -   1件:
64 
 35   Octaplas infusion   -   -   -   -   1件:
64 
 36   Octaplaslg®   -   -   -   -   1件:
64 
 37   Octostim   -   -   -   -   2件:
64,
288 
 38   Oms721   -   -   -   -   5件:
64,
66,
109,
222,
223 
 39   Oms721 100 mg/ml injection solution, oms00620646, oms620646, masp-2 antibody   -   -   -   -   2件:
64,
109 
 40   Oms721 185 mg/ml injection solution, oms00620646, oms620646, masp-2 antibody   -   -   -   -   2件:
64,
109 
 41   Plasma exchange (pe)   -   -   -   -   1件:
64 
 42   Prednisolone   Prednisolone   D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   38件:
11,
13,
25,
26,
35,
38,
39,
41,
43,
44,
45,
46,
49,
50,
51,
56,
60,
61,
63,
64,
65,
66,
75,
81,
84,
85,
95,
96,
97,
113,
145,
162,
222,
269,
271,
296,
299,
300 
 43   Prednisone   Prednisone   D00473   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   43件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
61,
63,
64,
65,
66,
81,
84,
85,
86,
95,
96,
97,
113,
162,
164,
222,
224,
228,
251,
283,
284,
285,
288,
299,
300,
331 
 44   Radamts-13   -   -   -   -   1件:
64 
 45   Recombinant a disintegrin and metalloproteinase with thrombospondin type-1 motifs   -   -   -   -   1件:
64 
 46   Recombinant a disintegrin and metalloproteinase with thrombospondin type-1 motifs 13   -   -   -   -   1件:
64 
 47   Rituximab   Rituximab   D02994   1件: MS4A1   1件: Hematopoietic cell lineage   42件:
11,
13,
14,
17,
35,
36,
43,
44,
45,
46,
49,
50,
51,
52,
53,
56,
60,
61,
63,
64,
65,
66,
83,
84,
85,
86,
93,
94,
96,
97,
162,
222,
223,
229,
256,
271,
283,
284,
285,
288,
300,
331 
 48   Shp655   -   -   -   -   1件:
64 
 49   Standard of care   -   -   -   -   8件:
6,
13,
14,
49,
51,
64,
79,
85 
 50   Standard plasma   -   -   -   -   1件:
64 
 51   Standrd of care treatment   -   -   -   -   1件:
64 
 52   Sulfate   Sulfate ion   -   -   -   22件:
2,
6,
11,
13,
26,
34,
36,
46,
49,
60,
61,
64,
66,
79,
86,
96,
222,
226,
265,
296,
297,
299 
 53   Sulfate, magnesium   Magnesium   -   -   -   1件:
64 
 54   Uniplas   -   -   -   -   1件:
64 
 55   Von willebrand factor   Von willebrand factor human   -   -   -   2件:
64,
288 

先頭へ